DMD and myxofibrosarcoma: In a cohort of 318 STS (103 sarcomas with complex genetic profiles (SCG) comprising 33 leiomyosarcomas (LMS), 23 myxofibrosarcoma, 37 undifferentiated pleomorphic sarcoma (UPS), and 10 others; 88 synovial sarcomas (SS); and 127 GISTs) (Table 1), analyzed by CGH array, DMD deletion was detected in 16.5% of all tumors (16.5% of sarcomas with complex genomic profiles, 21.6% of synovial sarcomas, and 14.2% of GIST) (Table 1).